R. Channick

EFFECTS OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST BOSENTAN IN PATIENTS WITH PULM HT: A RANDOMIZED PLACEBO CONTROLLED STUDY

G. Simonneau, O. Sitbon, R. Channick, 2001 .

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study ☆

G. Simonneau, O. Sitbon, R. Channick, 2002 .

Perfusion imaging heterogeneity during NO inhalation distinguishes pulmonary arterial hypertension (PAH) from healthy subjects and has potential as an imaging biomarker

V. J. Kelly, A. Waxman, J. Venegas, 2022, Respiratory Research.

Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension

K. Kerr, W. Auger, S. Jamieson, 2004, European Respiratory Journal.

Single arterial occlusion to locate resistance in patients with pulmonary hypertension

R. Naeije, P. Fesler, L. Rubin, 2003, European Respiratory Journal.

Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study

H. Ghofrani, R. Benza, G. Simonneau, 2018, Pneumologie.

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study.

D. Badesch, A. Frost, G. Simonneau, 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

P116 Effects of macitentan on right ventricular remodeling in pulmonary arterial hypertension – results from the REPAIR study interim analysis

A. Torbicki, D. Kiely, A. Tawakol, 2019, Pulmonary hypertension: advances in diagnosis and treatment.